(S)-N-<(tert-butyloxy)carbonyl>-2-pyrrolidinemethanol | 98253-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-N-<(tert-butyloxy)carbonyl>-2-pyrrolidinemethanol
• 英文别名: (S)-(-)-N-(2',2'-dimethylpropionyl)-2-pyrrolidinemethanol；(S)-N-pivaloylprolinol；(S)-N-[(tert-butyloxy)carbonyl]-2-pyrrolidinemethanol；1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-2,2-dimethylpropan-1-one
• CAS: 98253-71-5
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: MBEVFPFPTUNOQT-QMMMGPOBSA-N

物化性质

• 沸点：
  317.5±15.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-N-<(tert-butyloxy)carbonyl>-2-pyrrolidinemethanol 在 吡啶 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成
  参考文献：
  名称：

  Benzazepinone calcium channel blockers. 5. Effects on antihypertensive activity associated with N1 and aromatic substituents

  摘要：

  We have shown that the pyrrolidinylmethyl substituent on the lactam nitrogen (Nl) of benzazepinone and benzothiazepinone calcium channel blocking agents is resistant to metabolic deamination and generally increases the duration and potency of antihypertensive activity in spontaneously hypertensive rats (SHR) relative to (N,N-dimethylamino) ethyl analogs. Additionally, compounds possessing a substituent on the fused aromatic ring are more resistant to metabolic deacylation of the C3 hydroxy function, which may explain why aromatic substituents also frequently increase the potency and/or duration of antihypertensive activity. Our data also indicate the in antihypertensive activity associated with these structural modifications is independent of any effects of potency in vitro. Overall, we interpret these results to indicate that these structural modifications improve antihypertensive activity as a result of increased metabolic stability and, consequently, oral bioavailability.

  DOI：

  10.1021/jm00092a011
• 作为产物：
  描述：

  三甲基乙酰氯 、 L-脯氨醇 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 以82%的产率得到(S)-N-<(tert-butyloxy)carbonyl>-2-pyrrolidinemethanol
  参考文献：
  名称：

  手性酰胺膦控制的有机铜锂试剂的不对称共轭加成反应

  摘要：

  对有机铜锂与查尔酮和环烯酮的不对称共轭加成反应中手性酰胺基膦1-14的行为的研究表明，反应效率受许多因素控制，包括铜盐，溶剂，铜与有机锂的分子比以及结构基板的。在化学计量条件下，与环烯酮的反应使加合物的收率高达94％ee。

  DOI：

  10.1016/s0040-4020(99)00094-0

文献信息

• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Inhibitors of protein tyrosine kinase activity
  申请人：Raeppel Stephane

  公开号：US20080004273A1

  公开（公告）日：2008-01-03

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  这项发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，该发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，导致受体信号传导的抑制，例如抑制VEGF受体信号传导和HGF受体信号传导。更具体地，该发明涉及用于抑制VEGF受体信号传导和HGF受体信号传导的化合物、组合物和方法。该发明还提供了用于治疗细胞增殖性疾病和病况的组合物和方法。
• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。
• ARBOVIRUS INHIBITORS AND USES THEREOF
  申请人：Larsen Scott

  公开号：US20120252807A1

  公开（公告）日：2012-10-04

  The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as inhibitors of arboviruses.

  本发明涉及化学化合物、其发现方法以及其治疗用途。具体而言，本发明提供了作为虫媒病毒抑制剂的化合物。
• Structural requirements of an external, chiral amidophosphine ligand for asymmetric reaction of an organocopper reagent
  作者：Yuichi Nakagawa、Motomu Kanai、Yasuo Nagaoka、Kiyoshi Tomioka

  DOI：10.1016/0040-4039(96)01783-2

  日期：1996.10

  Three types of an external, chiral amide ligand, 2–6, were prepared and examination of their behavior in an asymmetric conjugate addition reaction of lithium dimethylcuprate with chalcone revealed the possibility for steric tuning to realize high selectivity.

  制备了三种类型的外部手性酰胺配体2-6，并检查了它们在不对称共轭加成反应中的行为，即二甲基二甲基碳酸锂与查尔酮的反应，揭示了进行空间调谐以实现高选择性的可能性。